MPR 01.12.21 Aspirin Use Tied to Incident Heart Failure in At Risk Adults. Medscape 25.11.21 Anticoagulantes en FA y reducción del riesgo de descenso cognitivo. Medscape 24.11.21 AAS y riesgo de IC. 22.11.21 ESC Heart Failure AAS y aumento del riesgo de IC. Kanie et al 25.10.21 Cochrane Nuevos antidiabéticos en cardiopatías. J.jacc.Nov 21 Doble terapia AAG tras PCI 1 mes nuevo estandar Ed. Medscape 25.10.21 Trombosis arterial retina. Medscape 28.10.21 Anticoagulación para ictus con funcion ventricular reducida. GI bleeding more common with rivaroxaban than other direct oral anticoagulants. October 12, 2021 2 min read Source/Disclosures Published by: Disclosures: Icelandic Centre for Research and Landspítali — The National University Hospital of Iceland provided funding for this study.
Björnsson reports no relevant financial disclosures. Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Rivaroxaban appeared associated with a higher rate of gastrointestinal bleeding than other direct oral anticoagulants, according to study results published in Annals of Internal Medicine. Patients treated with rivaroxaban (Xarelto, Janssen) demonstrated a 40% higher overall risk for GI bleeding and a 50% higher risk for major GI bleeding than those treated with apixaban (Eliquis; Bristol Myers Squibb, Pfizer).
“[The findings of this study] may help guide oral anticoagulant selection, especially for patients at high risk for GI bleeding,” Einar S. BOLCAN vol 4 num 4 Prevencion primaria secundaria ictus. Medscape 12.10.21 Mayor riesgo de sangrado con rivaroxaban respecto a otros ACOD. MPR 14.10.21 Marine Omega 3 Supplements Tied to Higher Atrial Fibrillation Risk. MPR 11.10.21 Altas dosis omega 3 y riesgo de FA. Medscape 07.10.21 Anticoagulación en AP. Chest Ag21 Guidelin and Expert Panel TVE 2021. Nejm 16.09.21 Impacto CV de los sustitutivos de la sal. Wayf.phtml?url= Ann Intern Med Sept 21 Major Bleeding During Extended Anticoagulation for Unprovoked VTE Abstract. Quick Takes Patients receiving long-term anticoagulation following an unprovoked VTE experience high rates of major bleeding with both DOAC and VKA therapy.
Major bleeding is associated with a substantial case-fatality risk among patients on long-term anticoagulation for unprovoked VTE. Key risk factors can help to predict which patients with unprovoked VTE are at risk for major bleeding with extended anticoagulation. Study Questions: What is the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked venous thromboembolic event (VTE)? Methods: The authors performed a systematic review of published randomized controlled trials (RCTs) and prospective cohort studies that reported major bleeding among patients with a first unprovoked VTE who were receiving oral anticoagulation for 6+ months after the initial 3-month treatment period. Results: Conclusions: JACC Sept 21 Hemorragia cerebral tras terapia AAG dual. MPR 16.09.21 Noncompliance to Apixaban for A Fib Due to Many Factors. Europace Sept 21 Colchicina y el corazón. Medcape 13.09.21 Es 1 mes de tp dual tras SCA segura MASTER DAPT y STOPDAPT 2.
Medscape 09.09.21 sobre las nuevas guidelines ESC de enfermedad valvular. JACC Sept 2021 Arritmias y patrón del sueño Ed. Medscape 03.09.21 STOP DAPT 2 ACS duración DAPT tras SCA 1 mes fracasa. Eur Heart J 30.08.21 GPC Prevención CV. Medscape 01.09.21 MASTER DAPT Doble tp post PCI en pac con alto riesgo sangrado. Medscape 27.08.21 Angina estabe en AP. Medscape 31.08.21 Rivaroxabán descenso de la FR más lento que Sintrom. Medscape 28.08.21 Edoxabán tras reemplazo valvular.
Medscape 29.08.21 Impacto de sustituir la sal. NEJM 28.08.21 Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk Abstract. Jamainternal ahuja 30.08.21 Deprescribir AAS. After a Stroke or TIA: New Guidelines to Prevent Recurrence. 2021 AHA Guideline PS tras ictus o TIA. MPR 24.08.21 Xarelto Approval Expands to Symptomatic PAD After Revascularization.
JACC.2021.Colchicina a bajas dosis en enf arterial coronaria. JAMA Newt Open lip 16.08.21 ACOD en pacientes de alto riesgo GI. Medscape 19.08.21 Sedentarismo aumenta riesgo ictus 40 60. 2019 Guideline isquemia MMII. Julio 21 EAP Statement AHA. Europace 2021 CHADSVASC AF Burden. Medscape 30.07.21 Varios comentarios Clarify angina estable. Medscape 23.07.21 Clarify angina estable. Guía ESC ACOD en FA 2021. Infarma marzo 2020 Retirada AC previa a procedimientos intervencionistas. Jamainternal ouellet 2021 Uso de anticoagulantes en demencia avanzada. Jamainternmed Parks 2021 end of life Ed. Medscape by Stroke 2021 Terapia dual vs AAS tras ictus o TIA. Medscape 21.07.21 Café y flutter. Jamainternal goldberger 2021 Consumo de café y taquiarritmias Ed. Europace 2021 CHA2DS2 VASc AFBurden Score. Medscape What Doctors Need to Know About NICE Atrial Fibrillation Guidance.
Progresión de early prevention subclinical atherosclerosis PESA. Enf coronaria isquémica. JACC.2021.Mineralocorticoides y flutter auricular. JACC Jul21 antiagregantes y anticoagulantes dos vías en prevención CV Ed. JACC Jul21 Rivaroxaban con AAS para EAP -Abstract. Circulation 2021 Speep apnea y CV disease AHA statement. AHA Guideline May 2021 PS ictus. Bmj 09.06.21 HBPM postcirugía en pac alto riesgo PERIOP2. Bmj jun 2021 clopidogrel vs terapia dual tras revascularización MA. Medscape 14.06.21 Antídotos ACOD y reducción sangrado. Best Practice Bulletin: May 21 - bpacnz - B-SAFE Tool for FA. B-SAFE: Atrial fibrillation clinical decision support tool Can you help us evaluate an electronic decision support tool which has been designed to assist primary care clinicians with management of atrial fibrillation?
In collaboration with cardiologists and stroke physicians from the National Cardiac and Stroke Networks we have created a tool to assist primary care clinicians in optimising cardiovascular treatments in patients with atrial fibrillation. The tool has been designed to provide an individualised check-list for treatments known to decrease the risk of stroke, myocardial infarction, heart failure and bleeding in patients with atrial fibrillation. It has also been designed to be quick and easy to use as part of routine care. Click here to view a short video about the tool. We now wish to evaluate this tool in the ‘Biomarkers for Stroke Prevention in Atrial Fibrillation using Electronic Decision Support (EDS)’ or B-SAFE study in practices that use Medtech-32 or Evolution.
JACC- 08.06.21 Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S. Bmj 09.06.21 HBPM PERIOP. NEJM Watch 08.06.21 Anticoagulation for Atrial Fibrillation Is Common Among People with Advanced Dementia at the End of Life. Medscape 31.05.21 Rivaroxabán en enf. arterial periférica con revasc. y riesgo de isquemia en MMII VoyAGER PAD. Jama baman 01.06.212021 FA. Jama polonsky 01.06.21 2021 Enfermedad arterial periférica sin isquemia crónica en MMII. BMJ 21.05,21 Dg y tto FA resumen Guía NICE.
Stroke 24.05.21 Guideline AHA ASA PS ictus. Lancet Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet Ed Antiplatelet therapy for secondary prevention of cardiovascular disease: challenging the certainties. J.jacc.2021.Cardiotoxicidad de antineoplásicos. Nejm 15.05.21 Adaptable Editorial. Does ADAPTABLE Inform Aspirin Dosing for Secondary Prevention? Nejm15.05.21 Adaptable dosis de AAS en PS. Medscape 15.05.21 AAS dosis y prevención CV. Clin Pharmacol Ther 2021 Uso de Anticoagulantes orales y función renal. MPR 17.05.21 Kidney Impairment Influences Safety, Efficacy of Anticoagulants for AFib. Bmj. 05.2021 Dg y tto FA en AP. BMJ 05.2021 Momento del Inicio del tto y resultados en FA.
Jamainternal parks 2021 ACO al final de la vida Ed. Jamainternal ouellet 10.05.2021 Less is more ACO al final de la vida demencia avanzada. Jama joshi 04.05.2021 Dg y manejo de angina esstable. MPR 04.05.21 Adding Aspirin to DOAC Therapy Without Clear Indication May Increase Bleeding Risk. Jamainternal schaefer 19.04.21 AAS y ACO efectos adversos. Jama joshi 04.05.21 Dg y tto Angina estable. JAMA marzo 2021 Consumo pescado y ECV. MPR 30.04.21 New DOAC Users Had Lower Risks for Ischemic Stroke, Major Bleeding vs New Warfarin Users.
Lancet 01.05.21 Antihipertensivos sin HTA para reducir RCV. Lancet 01.05.21 Antihipertensivos sin HTA para reducir RCV. Jama kamran 20.04.21 Terapia con antiagregantes en síndrome coronario agudo. Am J Emerg Med Feb21 Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Introduction: The efficacy of colchicine administration in patients undergoing percutaneous coronary intervention (PCI) remains controversial.
We conduct a systematic review and meta-analysis to explore the influence of colchicine administration versus placebo on treatment efficacy for PCI. Methods: We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through June 2020 for randomized controlled trials (RCTs) assessing the effect of colchicine administration versus placebo in patients with PCI. This meta-analysis is performed using the random-effect model. Results: Five RCTs involving 5526 patients are included in the meta-analysis. Conclusions: Colchicine treatment may be effective to reduce major adverse cardiovascular events in patients undergoing PCI. Keywords: Colchicine; Myocardial infarction; Percutaneous coronary intervention (PCI); Randomized controlled trials. 2021 GPC europea tto antiagregante en TAVI. 30.03.21 Ann Intern Med ACOD vs warfarina en FA valvular. 23.03.21 Inhib. de fosfodiesterasa vs alprostadil en enf coronaria.
MPR 17.03 Long Term Treatment of Aortic Dissection Antihypertensive Medications Compared. Medscape 10.03.21 ACOD tras cirugía valvular.